<DOC>
	<DOCNO>NCT01888302</DOCNO>
	<brief_summary>This pilot phase I trial study side effect best way give sirolimus , gemcitabine hydrochloride , cisplatin treat patient high risk cholangiocarcinoma recurrence liver transplant surgery . Sirolimus may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine hydrochloride , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving sirolimus gemcitabine hydrochloride cisplatin may prevent disease recurrence patient high risk recurrence liver transplant surgery .</brief_summary>
	<brief_title>Sirolimus , Gemcitabine Hydrochloride , Cisplatin Treating Patients At High Risk Cholangiocarcinoma Recurrence After Liver Transplant Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Assessment percentage patient able complete therapy 4 6 month post-registration . SECONDARY OBJECTIVES : I . To describe adverse event , rate dose reduction , quality life patient . II . To summarize timed endpoint time-to-recurrence , disease-free survival , overall survival , time treatment failure , time treatment relate grade 3+ adverse event . OUTLINE : Patients receive cisplatin intravenously ( IV ) 1 hour gemcitabine hydrochloride IV 30 minute day 1 8 , sirolimus orally ( PO ) daily three time weekly . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Histologic proof presence residual tumor liver explants /or positive resection margin Absolute neutrophil count ( ANC ) &gt; = 1500/μL obtain = &lt; 7 day prior registration Platelets ( PLT ) &gt; = 100,000/μL obtain = &lt; 7 day prior registration Total bilirubin = &lt; 1.5 x institutional upper limit normal ( ULN ) obtain = &lt; 7 day prior registration Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 2.5 x ULN obtain = &lt; 7 day prior registration ( = &lt; 5 x ULN patient liver metastasis ) Creatinine = &lt; 1.5 x Institutional ULN obtain = &lt; 7 day prior registration Alkaline phosphatase = &lt; 5 x institutional ULN obtain = &lt; 7 day prior registration Hemoglobin ( Hgb ) &gt; = 9.0 g/dL obtain = &lt; 7 day prior registration International normalized ratio ( INR ) partial thromboplastin ( PTT ) = &lt; 3.0 x ULN ( anticoagulation allow target INR = &lt; 3.0 x ULN stable dose warfarin stable dose low molecular weight [ LMW ] heparin &gt; 2 week time registration ) Fasting serum glucose &lt; 1.5 x ULN obtain = &lt; 7 day prior registration Fasting serum cholesterol = &lt; 300 mg/dL OR = &lt; 7.75 mmol/L AND fast triglyceride = &lt; 2.5 x ULN obtain = &lt; 90 day prior registration ; NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Ability provide inform consent Willingness return Mayo Clinic follow Life expectancy &gt; = 12 month Women childbearing potential : negative serum pregnancy test do = &lt; 7 day prior registration Four month post liver transplant Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Clinically significant cardiac disease , especially history myocardial infarction = &lt; 6 month , congestive heart failure ( New York Heart Association [ NYHA ] classification III IV ) require use ongoing maintenance therapy lifethreatening ventricular arrhythmia Taking strong inhibitor strong/moderate inducer cytochrome P450 ( CYP ) 3A4 Strong inhibitor CYP3A4/5 ; &gt; 5fold increase plasma area curve ( AUC ) value 80 % decrease clearance Clarithromycin ( Biaxin® , Biaxin XL® ) Conivaptan ( Vaprisol® ) Grapefruit juice Itraconazole ( Sporanox® ) Ketoconazole ( Nizoral® ) Mibefradil Nefazodone ( Serzone® ) Posaconazole ( Noxafil® ) Telaprevir ( Incivek® ) Telithromycin ( Ketek® ) Use follow inducer prohibit = &lt; 7 day prior registration Strong inducer CYP3A4/5 ; &gt; 80 % decrease AUC Avasimibe Carbamazepine ( Carbatrol® , Epitol® , Equetro™ , Tegretol® , TegretolXR® ) Phenytoin ( Dilantin® , Phenytek® ) Rifampin ( Rifadin® ) St. John 's wort Moderate inducer CYP3A4/5 ; 5080 % decrease AUC Bosentan ( Tracleer® ) Modafinil ( Provigil® ) Nafcillin Phenobarbital ( Luminal® ) Rifabutin ( Mycobutin® ) Troglitazone Any follow prior therapy : Chemotherapy = &lt; 4 week prior registration Mitomycin C/nitrosoureas = &lt; 6 week prior registration Immunotherapy = &lt; 4 week prior registration Biologic therapy = &lt; 4 week prior registration Radiation therapy = &lt; 4 week prior registration Radiation &gt; 25 % bone marrow prior registration Failure fully recover acute , reversible effect prior surgery chemotherapy regardless interval since last treatment Any follow study involve cytotoxic agent Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive low cluster differentiation ( CD ) 4 count ; Note : previous calcineurin inhibitor previous sirolimus use allow Current active malignancy , except nonmelanoma skin cancer carcinomainsitu cervix ; history prior malignancy , must receive specific treatment ( hormonal therapy ) cancer Current impairment gastrointestinal function gastrointestinal disease may significantly alter absorption sirolimus ( e.g. , active ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Current severely impair lung function ( i.e. , force expiratory volume 1 second [ FEV1 ] &lt; 1 liter ) Received immunization attenuate live vaccine = &lt; 7 day prior study entry study period ; NOTE : Close contact receive attenuated live vaccine avoid treatment sirolimus ; example live vaccine include intranasal influenza , measles , mumps , rubella , oral polio , Bacillus CalmetteGuérin ( BCG ) , yellow fever , varicella typhoid ( TY ) 21a typhoid vaccine Current severe hepatic impairment ; Note : A detailed assessment hepatitis B/C medical history risk factor must do screening patient ; hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) polymerase chain reaction ( PCR ) test require screening patient positive medical history base risk factor and/or confirmation prior HBV/HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>